Arrow drops opposition to Novartis patent for MS drug, despite win before IP Australia
Appeals 2020-10-12 2:35 pm By Miklos Bolza | Sydney
Please login to bookmark Close

The Federal Court has upheld Novartis’ appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au